CMS seeks sickle cell gene therapy makers to participate in Medicaid drug model

The Centers for Medicare & Medicaid Services March 7 invited drug makers in the Medicaid Drug Rebate Program that make federally approved gene therapies for sickle cell disease to apply through May 1 to participate in the Cell and Gene Therapy Access Model. Announced in January, the model will negotiate rebate agreements with participating drug makers in an effort to increase access to treatments for Medicaid patients with rare and severe diseases, beginning with sickle cell disease. CMS expects states to apply this summer to participate in the voluntary model, which may also include the Children’s Health Insurance Program, depending on state and manufacturer interest.
Related News Articles
Headline
The Department of Health and Human Services and the Centers for Medicare & Medicaid Services Aug. 21 announced the creation of a Healthcare Advisory…
Headline
The Centers for Medicare & Medicaid Services today announced a nationwide initiative aimed at reinforcing eligibility standards for Medicaid and the…
Headline
The Centers for Medicare & Medicaid Services has issued the 2025-2026 Medicaid Managed Care Rate Development Guide for states to use when setting managed…
Chairperson's File
The recently enacted One Big Beautiful Bill Act will bring big changes to health care. AHA President and CEO Rick Pollack joined me for a Leadership Dialogue…
Headline
The Congressional Budget Office today released its estimate of the budgetary effects of the One Big Beautiful Bill Act, as enacted. CBO projects the law will…
Headline
The Centers for Medicare & Medicaid Services July 17 issued two letters to states regarding policies on continuous eligibility and workforce initiatives.…